Skadden secured a dismissal for firm client Watson Pharmaceuticals, Inc., a generic drug manufacturer, in a reverse payment suit brought by the Federal Trade Commission and private purchasers related to the testosterone replacement drug Androgel. On February 23, Judge Thomas W. Thrash of the United States District Court for the Northern District of Georgia ruled that defendants, including the brand holder Solvay Pharmaceuticals, Inc. and Watson, did not violate federal and state antitrust laws when they settled patent infringement litigation with respect to generic versions of Androgel.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates